Volume 7 | Issue - 4
Volume 7 | Issue - 4
Volume 7 | Issue - 4
Volume 7 | Issue - 4
Volume 7 | Issue - 4
Background: Data on outcomes of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV)-related extrahepatic manifestations (EHMs) is scarce. We aimed to assess the safety and efficacy of sofosbuvir (SOF)-based regimens in HCVrelated EHMs.